Genetic factors that influence why some people have poor response to standard therapies often overlap with the biology underlying bipolar disorder itself, while other variants specifically affect medication response pathways. Large-scale genomic studies and pharmacogenetic investigations point to a mixed picture in which common risk loci, rare functional variants, and aggregated polygenic burden all play roles.
Common bipolar risk loci and their relevance to resistance
Genome-wide association studies identify robust loci such as CACNA1C and ANK3 that increase susceptibility to bipolar disorder and likely raise the baseline probability of more severe or treatment-refractory illness through effects on neuronal excitability and axonal function. Evidence from the Psychiatric Genomics Consortium highlights these loci as reproducible contributors to bipolar risk. Francis J. McMahon National Institute of Mental Health has reviewed how these shared risk alleles shape illness course and interact with environmental stressors to influence long-term outcome. Presence of these alleles does not determine resistance alone, but they increase vulnerability that can manifest as poor response to first-line treatments.
Pharmacogenetic variants linked to poor response
Variants in genes involved in synaptic signaling and pharmacodynamic pathways have been associated with differential response and possible resistance. The BDNF Val66Met polymorphism has been studied for its influence on illness course and treatment outcomes, and investigators such as John R. Kelsoe University of California San Diego have explored how neurotrophic signaling and downstream kinases like GSK3B modulate lithium responsiveness. Variants in serotonergic and glutamatergic system genes, including SLC6A4 and GRIN2A or GRIN2B, have been implicated by multiple research groups at the National Institute of Mental Health in shaping response to antidepressants and agents targeting glutamate, thereby affecting apparent treatment resistance when standard agents fail.
Polygenic risk scores that aggregate many small-effect variants are increasingly shown to correlate with poorer treatment trajectories and greater likelihood of complex polypharmacy. This suggests resistance is often multifactorial rather than driven by a single “resistance gene.”
Clinical and social consequences arise when genetic findings are applied. Genetic stratification could improve personalization of mood-stabilizing choices but risks inequity because allele frequencies and studied cohorts are biased toward European ancestry. Cultural factors, access to genomic testing, and environmental contributors such as early-life stress interact with genetic predisposition to shape resistance, so translation to practice requires careful, evidence-based frameworks and replication across diverse populations.